A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Launched by MERCK SHARP & DOHME LLC · May 13, 2009

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant has Type 2 Diabetes (T2DM)
• • Participant is either: Not on an oral antihyperglycemic medication for at least 6 weeks; on a single oral antihyperglycemic medication that is not a peroxisome proliferator-activated gamma (PPAR-gamma) agonist (e.g. Avandia); OR on a combination of no more than two antihyperglycemic medications that are not PPAR-gamma) agonists
• • Participant has not received insulin for at least 6 months
• • Participant has not been treated with a PPAR-gamma agonist for at least 12 weeks
• • Participant has been a nonsmoker for at least 6 months
• • Female participants who are non-pregnant and highly unlikely to conceive due to surgical sterilization, post-menopausal status, not heterosexually active, or willing to use 2 birth control methods
• Exclusion Criteria:
• • Participant has a history of stroke, seizures, or neurological disorders
• • Participant cannot tolerate insulin or propranolol
• • Participant has a history of asthma, emphysema or chronic bronchitis
• • Participant is on a weight loss program that is not in the maintenance phase or has been treated with a weight loss medication within 8 weeks of screening
• • Participant is on or may require treatment with drugs that affect the immune system or with corticosteroids
• • Participant has a history of heart failure or coronary artery disease
• • Participant has a history of uncontrolled high blood pressure
• • Participant is Human Immunodeficiency (HIV), hepatitis B or hepatitis C positive
• • Participant has a history of Type 1 diabetes
• • Participant has a history of hypoglycemia unawareness documented by a blood glucose concentration \< 55 mg/dL (3.1 mol/L) without symptoms of hypoglycemia.